Not logged in Share Save
Share Save
Share Save
Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC) Wolpin, B.; Hong, D.; Spira, A.; Starodub, A.; Park, W.; Sommerhalder, D.; Valerin, J.; Barve, M.; Punekar, S.; Pelster, M.; Herzberg, B.; Azad, N.; Aung, K.; Hecht, J. R.; Cheng, L.; Vora, R.; Salman, Z.; Zhang, Y.; Lin, T.; Garrido-Laguna, I. Share Save
Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy O'Hara, Mark H.; Wattenberg, Max; Garrido-Laguna, Ignacio; O'Reilly, Eileen M.; Yellin, Michael; Keler, Tibor; Gargano, Michele; Niles, Nick; Drees, Jeremy; Bose, Nandita; Beatty, Gregory L. Share Save
Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy O'Hara, Mark H.; Wattenberg, Max; Garrido-Laguna, Ignacio; O'Reilly, Eileen M.; Yellin, Michael; Keler, Tibor; Gargano, Michele; Niles, Nick; Drees, Jeremy; Bose, Nandita; Beatty, Gregory L. Share Save
Colon Cancer, Version 3.2024 Benson III, Al B.; Venook, Alan P.; Adam, Mohamed; Chang, George; Chen, Yi-Jen; Ciombor, Kristen K.; Cohen, Stacey A.; Cooper, Harry S.; Deming, Dustin; Garrido-Laguna, Ignacio; Grem, Jean L.; Haste, Paul; Hecht, J. Randolph; Hoffe, Sarah; Hunt, Steven; Hussan, Hisham; Johung, Kimberly L.; Joseph, Nora; Kirilcuk, Natalie; Krishnamurthi, Smitha; Malla, Midhun; Maratt, Jennifer K.; Messersmith, Wells A.; Meyerhardt, Jeffrey; Miller, Eric D.; Mulcahy, Mary F.; Nurkin, Steven; Overman, Michael J.; Parikh, Aparna; Patel, Hitendra; Pedersen, Katrina; Saltz, Leonard; Schneider, Charles; Shibata, David; Shogan, Benjamin; Skibber, John M.; Sofocleous, Constantinos T.; Tavakkoli, Anna; Willett, Christopher G.; Wu, Christina; Gurski, Lisa A.; Snedeker, Jenna; Jones, Frankie Share Save
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma Wattenberg, Max M.; Colby, Sarah; Garrido-Laguna, Ignacio; Xue, Yuqing; Chang, Renee; Delman, Devora; Lee, Jesse; Affolter, Kajsa; Mulvihill, Sean J.; Beg, M. Shaalan; Wang-Gillam, Andrea; Wade III, James Lloyd; Guthrie, Katherine A.; Chiorean, E. Gabriela; Chiorean, Gabriela; Ahmad, Syed A.; Lowy, Andrew M.; Philip, Philip Agop; Sohal, Davendra P. S.; Beatty, Gregory L. Share Save
Share Save
Share Save
RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma Lim, Kian-Haut; Hidalgo, Manuel; O'Hara, Mark H.; Spencer, Kristen R.; Garrido-Laguna, Ignacio; DeNardo, David G.; Bhambhani, Vijeta; Patrick, Gloria; Cheng, Yaofeng; Coma, Silvia; Pachter, Jonathan A.; Denis, Louis J. Share Save
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021) Li, Daneng; Loriot, Yohann; Burgoyne, Adam M.; Cleary, James M.; Santoro, Armando; Lin, Daniel; Aix, Santiago Ponce; Garrido-Laguna, Ignacio; Sudhagoni, Ramu; Guo, Xiang; Andrianova, Svetlana; Paulson, Scott Share Save
Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001 Spira, Alexander I.; Starodub, Alexander N.; Arbour, Kathryn C.; Sommerhalder, David; Wolpin, Brian M.; Barve, Minal; Garrido-Laguna, Ignacio; Punekar, Salman; Pelster, Meredith; Kar, Sumit; Wong, Jamie; Lin, Tong; Raman, Rakesh; Tao, Lin; Salman, Zeena; Wang, Xiaolin; Gustafson, W. Clay; Hong, David S. Share Save
MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A Yap, Timothy A.; Schram, Alison; Lee, Elizabeth K.; Simpkins, Fiona; Weiss, Mia C.; LoRusso, Patricia; Hojgaard, Martin; Carneiro, Benedito A.; Moy, Ryan H.; Garrido-Laguna, Ignacio; Koehler, Maria; Unger, Thaddeus J.; Bacque, Emeline; Aguado-Fraile, Elia; Sethuraman, Sunantha; Dhake, Snehal; Liu, Yajun; Fretland, Adrian J.; Sun, Xizi; Xu, Yi; Hawkey, Nathan; Truong, Jen; Lheureux, Stephanie Share Save
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors Bauer, Todd M.; Santoro, Armando; Lin, Chia-Chi; Garrido-Laguna, Ignacio; Joerger, Markus; Greil, Richard; Spreafico, Anna; Yau, Thomas; Goebeler, Maria-Elisabeth; Huetter-Kroenke, Marie Luise; Perotti, Antonella; Juif, Pierre-Eric; Lu, Darlene; Barys, Louise; Cremasco, Viviana; Pelletier, Marc; Evans, Helen; Fabre, Claire; Doi, Toshikiko Share Save
Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) Arbour, K. C.; Punekar, S.; Garrido-Laguna, I.; Hong, D. S.; Wolpin, B.; Pelster, M. S.; Barve, M.; Starodub, A.; Sommerhalder, D.; Chang, S.; Zhang, Y.; Salman, Z.; Wang, X.; Gustafson, C.; Spira, A. I. Share Save
Share Save
Share Save
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden Florou, Vaia; Floudas, Charalampos S.; Maoz, Asaf; Naqash, Abdul Rafeh; Norton, Carter; Tan, Aik Choon; Sokol, Ethan S.; Frampton, Garrett; Soares, Heloisa P.; Puri, Sonam; Swami, Umang; Wilky, Breelyn; Hosein, Peter; Trent, Jonathan; Lopes, Gilberto de Lima; Park, Wungki; Garrido-Laguna, Ignacio Share Save
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial Ahnert, J. Rodon; Tan, D. S. -W; Garrido-Laguna, I.; Harb, W.; Bessudo, A.; Beck, J. T.; Rottey, S.; Bahary, N.; Kotecki, N.; Zhu, Z.; Deng, S.; Kowalski, K.; Wei, C.; Pathan, N.; Laliberte, R. J.; Messersmith, W. A. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
